An Open‐Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7‐Day Triple Therapy With Bismuth Versus 14‐Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents

To achieve eradication rates > 90%, the ESPGHAN/NASPGHAN guidelines for pediatric Helicobacter pylori infection recommend tailored antimicrobial therapy using sufficiently high doses over 10–14 days. However, prolonged treatment often leads to suboptimal compliance in children, which is a major contributor to reduced eradication rates. To address this, we evaluated the efficacy and safety of a shorter, 7 day triple therapy with bismuth compared with the 14 day standard triple therapy without bismuth in H. pylori infected children.